Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Research & Development (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Research & Development for 12 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 42.82% year-over-year to $13.6 million, compared with a TTM value of $45.0 million through Sep 2025, up 148.31%, and an annual FY2024 reading of $24.4 million, up 77.29% over the prior year.
  • Research & Development was $13.6 million for Q3 2025 at Avalo Therapeutics, down from $14.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $25.2 million in Q1 2021 and bottomed at $1.2 million in Q3 2023.
  • Average Research & Development over 5 years is $8.7 million, with a median of $8.5 million recorded in 2022.
  • The sharpest move saw Research & Development tumbled 82.25% in 2023, then surged 663.04% in 2024.
  • Year by year, Research & Development stood at $11.5 million in 2021, then plummeted by 46.38% to $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then surged by 338.24% to $8.2 million in 2024, then surged by 66.49% to $13.6 million in 2025.
  • Business Quant data shows Research & Development for AVTX at $13.6 million in Q3 2025, $14.1 million in Q2 2025, and $9.1 million in Q1 2025.